Ekso Bionics Holdings, Inc. (EKSO): Price and Financial Metrics
EKSO Stock Summary
- Ekso Bionics Holdings Inc's market capitalization of $74,591,408 is ahead of merely 13.64% of US-listed equities.
- As for revenue growth, note that EKSO's revenue has grown -36.18% over the past 12 months; that beats the revenue growth of merely 9.47% of US companies in our set.
- Ekso Bionics Holdings Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -14.35%, greater than the shareholder yield of just 15.89% of stocks in our set.
- Stocks that are quantitatively similar to EKSO, based on their financial statements, market capitalization, and price volatility, are CYRX, NVRO, WEI, ECOR, and BIOL.
- EKSO's SEC filings can be seen here. And to visit Ekso Bionics Holdings Inc's official web site, go to www.eksobionics.com.
EKSO Stock Price Chart Interactive Chart >
EKSO Price/Volume Stats
| Current price | $5.87 | 52-week high | $14.98 |
| Prev. close | $5.92 | 52-week low | $2.25 |
| Day low | $5.10 | Volume | 331,700 |
| Day high | $6.09 | Avg. volume | 507,044 |
| 50-day MA | $8.28 | Dividend yield | N/A |
| 200-day MA | $6.01 | Market Cap | 73.96M |
Ekso Bionics Holdings, Inc. (EKSO) Company Bio
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Asia. The company was founded in 2005 and is based in Richmond, California
Latest EKSO News From Around the Web
Below are the latest news stories about Ekso Bionics Holdings Inc that investors may wish to consider to help them evaluate EKSO as an investment opportunity.
Ekso Bionics Teams Up with Performance Contracting, Inc. for Innovative Testing Approach of EVO™ TechnologyRICHMOND, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Performance Contracting, Inc. (“PCI”), a leading U.S. specialty contractor, is the latest company in the construction vertical to implement field testing of EVO™ exoskeleton vests. Over the course of a year, PCI employees in six Bay Area counties have committed to testing EVO™ exoskeleton vests for the Company’s continued product development and innovation. “We are excited that PCI’s workforce will benefit from our novel EVO technology,” commented Michael Pratt, Vice President of Ekso Bionics. “Companies within the construction vertical are starting to recognize that EVO provides... |
Ekso Bionics to Present at the H.C. Wainwright Global Life Sciences ConferenceRICHMOND, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Glenn, Chief Financial Officer, will present at the H.C. Wainwright Global Life Sciences Conference held on March 9 – 10, 2021. A company presentation will be available to view on-demand as of 4:00 AM PT / 7:00 AM ET, Tuesday, March 9, 2021 throughout the entirety of the conference and available on the investor section of the Company’s website at www.eksobionics.com, or by clicking here. About Ekso Bionics® Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial appli... |
Ekso Bionics Holdings EPS misses by $0.18, misses on revenueEkso Bionics Holdings (EKSO): Q4 GAAP EPS of -$0.48 misses by $0.18.Revenue of $2.25M (-39.5% Y/Y) misses by $0.33M.Press Release... |
Ekso Bionics' (EKSO) CEO Jack Peurach on Q4 2020 Results - Earnings Call TranscriptEkso Bionics Holdings, Inc. (EKSO) Q4 2020 Earnings Conference Call February 25, 2020 4:30 PM ET Company Participants Matt Steinberg – Investor Relations-Lazar Finn Partners Jack Peurach – President and Chief Executive Officer Bill Shaw – Chief Commercial Officer Jack Glenn – Chief Financial Officer Conference Call Participants Sean Kang... |
Earnings Preview: Ekso Bionics HoldingsOn Thursday, February 25, Ekso Bionics Holdings (NASDAQ:EKSO) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS. Earnings And Revenue Analysts are predicting Ekso Bionics Holdings will report a loss of $0.3 per share on revenue of $2.58 million. Ekso Bionics Holdings EPS in the same period a year ago totaled $0.04. Sales were $3.72 million. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street analysts who study this company will publish analyst ... |
EKSO Price Returns
| 1-mo | -38.66% |
| 3-mo | 6.34% |
| 6-mo | N/A |
| 1-year | 21.65% |
| 3-year | -77.64% |
| 5-year | -93.86% |
| YTD | -4.24% |
| 2020 | 4.52% |
| 2019 | -68.47% |
| 2018 | -41.78% |
| 2017 | -46.48% |
| 2016 | -44.26% |
Continue Researching EKSO
Want to do more research on Ekso Bionics Holdings Inc's stock and its price? Try the links below:Ekso Bionics Holdings Inc (EKSO) Stock Price | Nasdaq
Ekso Bionics Holdings Inc (EKSO) Stock Quote, History and News - Yahoo Finance
Ekso Bionics Holdings Inc (EKSO) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...